Bucillamine

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

布西拉明可防止高危器官移植中的缺血/再灌注损伤并抑制 VEGF 的产生。

Bucillamine protects against Ischemia/reperfusion injury in high-risk organ transplants and inhibits the production of VEGF. Bucillamine is an orally active sulfhydryl donor and antioxidant with antirheumatic and antiangiogenic properties. Bucillamine can be used for studies about choroidal neovascularization and rheumatoid arthritis.(In Vivo):In rats subjected to liver transplants, Bucillamine significantly enhances survival and protected against hepatic injury. Subconjunctival injection of Bucillamine significantly reduces the leakage and size of experimental CNV in rats.

——

Bucillamine significantly enhances survival and protected against hepatic injury in rats subjected to liver transplants.Bucillamine (Subconjunctival injection) significantly reduces the leakage and size of experimental CNV in rats.

DE-019 | DE 019 | DE019 | SA96 | Thiobutarit | Tiobutarit |

Angiogenesis

VEGFR

Endogenous Metabolite

——

——

65002-17-7

223.31

C7H13NO3S2

>98% (HPLC)

In Vitro:?H2O : 5 mg/mL (22.39 mM)

CC(C)(S)C(=O)NC(CS)C(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years